Enveric Biosciences Inc Dossier
Qualitative Analysis
Business overview
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a clinical-stage development biotechnology company dedicated to the discovery and development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its proprietary discovery and development platform, Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. The company's lead asset is EB-003, a potential first-in-class neuroplastogen designed to promote neuroplasticity without inducing hallucinations, thereby reducing the treatment burden and enabling repeat-dose outpatient care. Enveric is also developing EB-002 (formerly EB-373), a next-generation synthetic prodrug of the active metabolite psilocin.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing and advancing the lead non-hallucinogenic neuroplastogen candidate, EB-003, through IND-enabling preclinical studies toward first-in-human clinical trials.
Expected impact: Establishes a novel therapeutic paradigm for treatment-resistant depression, PTSD, and anxiety disorders without hallucinogenic side effects, allowing outpatient administration.
Leveraging the company's extensive intellectual property library (Psybrary) of psychedelic-inspired molecules to secure out-licensing and partnering agreements with third-party developers.
Expected impact: Generates non-dilutive revenue through upfront, development, and sales milestone payments, plus royalties, while allowing the company to focus resources on EB-003.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire MagicMed's robust portfolio of psychedelic-derived molecules and its proprietary drug discovery platform, the Psybrary, expanding Enveric's pipeline into next-generation neuroscience therapeutics.
Financial impact: Expanded the company's IP estate and brought in approximately $4.0 million CAD in cash from the MagicMed treasury at closing.
Strategic Partnerships
Out-licensed the EVM201 program and drug candidate EB-002 (a synthetic prodrug of psilocin) to allow Enveric to focus exclusively on advancing EB-003.
Terms: Enveric is eligible to receive up to $62 million in upfront, development, and sales milestone payments, plus tiered single-digit royalties on future sales.
Executed two licensing agreements for cannabinoid-COX-2 conjugate compounds for pharmaceutical and potential non-pharmaceutical joint disease applications.
Terms: Terms include potential milestone payments and royalties on future product sales.
Expanded collaboration focused on the development of topical cannabinoid pharmaceutical products.
Terms: Not explicitly disclosed.